Adiso Therapeutics: Revolutionizing Inflammation Treatment

Picture this: agonizing abdominal pain, persistent trips to the bathroom, and a body that struggles to absorb vital nutrients. It's a grim reality for those living with Ulceritive Colitus, a type of inflammatory bowel syndrome affecting countless Americans each year. Meet Adiso Therapeutics, a dynamic company that's shaking up the field of drug development with its focus on this underserved field.

Adiso's star player, ADS024, is currently on Phase 1B clinical trials for mild-to-moderate UC. The power of the drug comes from targeting neutrophils, a type of white blood cells largely related to inflammation. The molecule can not only deactivate them in the bowels, but also disable messanger proteins which cause them to travelling there in the first place. The drug's compounds will only come into action once it reaches the bowels, meaning that it will not get absorbed anywhere else in the body, ensuring less side effects.

Adiso's pursuit of innovation doesn't stop there. They're exploring using the molecule for recurrive UC as well, along with a discovery phase process of molecules for respiratory inflammation.

Scott Megaffin and Jennifer Locke, the firm's cofounders, firmly believe that these groundbreaking mechanisms of action hold the key to tackling inflammatory diseases. Current treatments for UC are lackluster at best, leaving patients longing for more effective solutions. Adiso is determined to be the cure society has been awaiting.

While the path will likely take another decade and include rigorous clinical trials, regulatory approvals, and partnerships with drug manufacturers and distributors, Adiso remains undeterred, and it appears that investors agree. Despite only being founded in 2022, Adiso has already secured substantial funding. A remarkable 62 million EUR was raised in their Series B round, led by the Morningside Group. With this financial windfall, Adiso is poised to turbocharge their clinical trials, fine-tune their drug candidates, and bring newfound hope to patients yearning for better treatment options.

In a society where chronic inflammation affects millions, Adiso's pursuit of a cure offers hope and optimism. As we celebrate their achievements, we eagerly await the next chapter in their remarkable journey.